Pieris Pharmaceuticals, Inc. (PIRS)
NASDAQ: PIRS · Real-Time Price · USD
16.01
+0.54 (3.49%)
Nov 20, 2024, 4:00 PM EST - Market closed
Pieris Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1.35 | 42.81 | 25.9 | 31.42 | 29.32 | 46.28 | Upgrade
|
| Revenue Growth (YoY) | -97.15% | 65.28% | -17.56% | 7.14% | -36.64% | 59.03% | Upgrade
|
| Cost of Revenue | 41.8 | 41.8 | 52.98 | 66.66 | 46.53 | 55 | Upgrade
|
| Gross Profit | -40.45 | 1.01 | -27.08 | -35.24 | -17.21 | -8.72 | Upgrade
|
| Selling, General & Admin | 13.47 | 16.85 | 16.39 | 16.59 | 16.71 | 18.44 | Upgrade
|
| Research & Development | -35.82 | - | - | - | - | - | Upgrade
|
| Operating Expenses | -22.35 | 16.85 | 16.39 | 16.59 | 16.71 | 18.44 | Upgrade
|
| Operating Income | -18.1 | -15.84 | -43.47 | -51.83 | -33.92 | -27.16 | Upgrade
|
| Interest & Investment Income | 1.07 | 1.85 | 0.72 | 0 | 0.51 | 1.71 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.57 | -0.3 | 0.93 | 2.4 | -3.19 | -1.19 | Upgrade
|
| EBT Excluding Unusual Items | -20.6 | -14.3 | -41.83 | -49.42 | -36.6 | -26.63 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.05 | 0.05 | 0.38 | - | -0.47 | 1.16 | Upgrade
|
| Asset Writedown | 0.98 | -13.91 | - | - | - | - | Upgrade
|
| Other Unusual Items | 3.61 | 3.61 | 8.17 | 3.69 | - | - | Upgrade
|
| Pretax Income | -15.95 | -24.54 | -33.28 | -45.74 | -37.07 | -25.47 | Upgrade
|
| Income Tax Expense | - | - | - | - | 0.16 | - | Upgrade
|
| Net Income | -15.95 | -24.54 | -33.28 | -45.74 | -37.23 | -25.47 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 2.83 | Upgrade
|
| Net Income to Common | -15.95 | -24.54 | -33.28 | -45.74 | -37.23 | -28.3 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 21.29% | 21.43% | 14.91% | 18.48% | 7.62% | -4.63% | Upgrade
|
| EPS (Basic) | -12.53 | -21.80 | -35.89 | -56.69 | -54.67 | -44.72 | Upgrade
|
| EPS (Diluted) | -12.53 | -21.80 | -35.89 | -56.69 | -54.67 | -44.72 | Upgrade
|
| Free Cash Flow | -27.99 | -53.99 | -60.97 | -8.61 | -48.62 | -54.93 | Upgrade
|
| Free Cash Flow Per Share | -21.99 | -47.96 | -65.76 | -10.67 | -71.40 | -86.80 | Upgrade
|
| Gross Margin | - | 2.36% | -104.55% | -112.16% | -58.68% | -18.84% | Upgrade
|
| Operating Margin | -1338.54% | -37.01% | -167.84% | -164.97% | -115.68% | -58.68% | Upgrade
|
| Profit Margin | -1179.96% | -57.33% | -128.47% | -145.58% | -126.97% | -61.15% | Upgrade
|
| Free Cash Flow Margin | -2069.97% | -126.12% | -235.40% | -27.40% | -165.82% | -118.69% | Upgrade
|
| EBITDA | -18.3 | -13.94 | -40.7 | -49.37 | -31.61 | -26.53 | Upgrade
|
| EBITDA Margin | - | -32.56% | -157.15% | -157.15% | -107.80% | -57.32% | Upgrade
|
| D&A For EBITDA | -0.2 | 1.9 | 2.77 | 2.46 | 2.31 | 0.63 | Upgrade
|
| EBIT | -18.1 | -15.84 | -43.47 | -51.83 | -33.92 | -27.16 | Upgrade
|
| EBIT Margin | - | -37.01% | -167.84% | -164.97% | -115.68% | -58.68% | Upgrade
|
| Revenue as Reported | 1.35 | 42.81 | 25.9 | 31.42 | 29.32 | 46.28 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.